Declines in alkaline phosphatase (ALP) may predict better outcomes in patients receiving treatment with radium-223 for metastatic castration-resistant prostate cancer (mCRPC), according to study findings presented at the European Society for Medical Oncology 2016 congress in Copenhagen.

As part of a prospective single-arm phase 3b study, investigators led by Daniel Heinrich, MD, of Akershus University Hospital in Lorenskog, Norway, studied 696 mCRPC patients who received at least 1 radium-223 cycle in an international early access program. At week 12, 398 patients (57%) had a confirmed decline in ALP from baseline and 298 (43%) did not.

Compared with the group that did not have an ALP decline, the group that did had a significant 70% decreased risk of death and a 53% decreased risk of first symptomatic skeletal event, Dr Heinrich and his colleagues reported.

More patients with a confirmed ALP decline received 5–6 radium-223 injections than those with no ALP decline (94% vs 33%).

The investigators noted that identifying a reliable marker of efficacy for radium-223 would help in the clinical management of mCRPC patients.

Related Articles

Reference

1. Heinrich D, et al. Changes in alkaline phosphatase  (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). Findings presented at the European Society for Medical Oncology 2016 congress in Copenhagen, October 7–11. Poster 751P. Ann Oncol 2016;27(Suppl 6):vi257.